Methuosis key gene ARF6 as a diagnostic, prognostic and immunotherapeutic marker for prostate cancer: based on a comprehensive pan-cancer multi-omics analysis
ARF6 is a key regulator of Methuosis in prostate cancer, contributing to tumor progression, metastasis, and resistance to treatment. Our findings support the potential of ARF6 as a diagnostic, prognostic, and immunotherapeutic target in prostate cancer. Further experimental validation is needed to confirm these observations and to explore the therapeutic implications of targeting ARF6 in cancer treatment.
Authors
- Chengyu You (ORCID: https://orcid.org/0000-0002-7692-9401)
- Liangliang Qing
- Zhilong Dong (ORCID: https://orcid.org/0009-0001-8862-4445)
- Yongjin Yang (ORCID: https://orcid.org/0000-0002-0879-3426)
- Qingchao Li (ORCID: https://orcid.org/0000-0002-0307-0085)
- Wenbo Xu (ORCID: https://orcid.org/0000-0002-3994-6077)
Institutions
- Lanzhou University Second Hospital (CN)
- Gansu Provincial Center for Disease Control and Prevention (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1007/s12672-025-02275-y
- Citations
- 2
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Fundamental Research Funds for the Central Universities